Colorectal Cancer Articles

Microbial Metabolomics: A Search for the Missing Link to Cancer
Thanks to technological advances, the past several decades have witnessed a blossoming appreciation of the varied composition of these microbial communities, their complex and dynamic relationship with the host, and the way they affect health and disease.
Byrne Lee, MD, discusses regional treatment strategies for patients with metastatic colorectal cancer.
Future of CRC Rests in Greater Genomic Understanding
Marwan Fakih, MD, discusses recent trials in colorectal cancer and highlights other ongoing research in the field.
Online Tool Estimates the Risk for Lynch Syndrome
Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.
Pashtoon M. Kasi, MD, MBBS, MS, provides an overview of the potential for liquid biopsies in CRC and advances being made in the treatment landscape.
Immune-Oncology Role Continues to Be Refined in GI Cancer
Michael J. Overman, MD, highlights new combination agents under investigation for the treatment of patients with GI cancers—specifically CRC—and challenges that still need to be addressed.
FDA Approves 23andMe Consumer Test for Hereditary CRC Syndrome
The FDA has cleared a direct-to-consumer genetic test for a risk report on MUTYH-associated polyposis, a hereditary colorectal cancer syndrome.
Bekaii-Saab Brings Insight to Precision Medicine in GI Cancers
Tanios Bekaii-Saab, MD, discusses ways to further develop precision medicine within the treatment of patients with gastrointestinal cancers.
Durvalumab/Tremelimumab Combo Improves Efficacy in Refractory CRC
The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.
Single-Agent Durvalumab Elicits Responses in MSI-H CRC
The PD-L1 inhibitor durvalumab achieved objective responses in about a fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer.
Publication Bottom Border
Border Publication